Drug vis‐à‐vis consumer: a retrospection

Author:

Das Praufulla Kumar

Abstract

PurposeDrugs and pharmaceuticals assume importance in the healthcare system today for their capacity to replace costly treatments like surgery. The pharmaceutical industry is considered capital intensive and building a new product costs as much as $900 million. Though the cost of developing a new product is significantly low in a country like India, it is substantial. Therefore, perhaps, companies try to go for incremental innovation. This apart, finding new symptoms to promote products, hiding major side effects, publishing data mixing the outcomes of different studies, publishing major outcomes in reputed journals and poor outcome studies in less important journals are some of the strategies being adopted by pharmaceutical companies. The purpose of this paper is to analyze these issues and their impacts on the Indian economy. As most of the Indian pharmaceutical companies are in private hands, this paper focuses on the possible plight of Indian poor in the changing world order.Design/methodology/approachThis paper draws upon earlier research undertaken by the author. His experience from the pharmaceutical industry as well as the published works of other researchers also helped complete the work.FindingsThe analysis of this paper indicates that in order to avoid the loss of revenue and to keep their businesses floating, drug and pharmaceutical companies resort to information manipulation.Research limitations/implicationsThe research is limited to the author's ability to review literatures in the field of marketing and corporate ethics related to drugs and pharmaceuticals. As competition and economic liberalization would have a significant impact on pharmaceutical brand‐success, therefore, perhaps, drug companies would resort to manipulations for survival. This paper is an attempt to alert the society to these sorts of information laundering.Practical implicationsThis paper would perhaps provide consumers with necessary information to understand the unethical practices being adopted by drug companies and help them consider what exactly to look for and would press for their right to good health.Originality/valueThis paper is the record of original work done by the author. It would probably fulfil an identified need and would perhaps help the society fight unethical practices being adopted by pharmaceutical companies.

Publisher

Emerald

Subject

General Social Sciences,Economics and Econometrics

Reference20 articles.

1. Alex, C., Wong, A., Chavez, M. and Chang, S. (1998), Allergic to People? The Manipulation of Information by Pharmaceutical Companies Case Study: Paxil.

2. Alison, B. (2008), Side Effects: A Prosecutor, a Whistle Blower, and a Best Selling Anti‐depressant on Trial, Workman Publishing, New York, NY.

3. Angell, M. (2004), “The truth about drug companies”, The New York Review of Books, Vol. 15, 15 July, available at: www.nybooks.com/article/17244.

4. Angell, M. and Rehman, A.S. (2002), “Patients, profits and American medicine: conflicts of interest in the testing and marketing of new drugs”, Daedalus, Vol. 103 No. 2, pp. 102‐11.

5. Conrad, P. and Leiter, V. (2004), “Modernization, markets and consumers”, Journal of Health and Social Behavior, Vol. 45, pp. 158‐76.

Cited by 1 articles. 订阅此论文施引文献 订阅此论文施引文献,注册后可以免费订阅5篇论文的施引文献,订阅后可以查看论文全部施引文献

同舟云学术

1.学者识别学者识别

2.学术分析学术分析

3.人才评估人才评估

"同舟云学术"是以全球学者为主线,采集、加工和组织学术论文而形成的新型学术文献查询和分析系统,可以对全球学者进行文献检索和人才价值评估。用户可以通过关注某些学科领域的顶尖人物而持续追踪该领域的学科进展和研究前沿。经过近期的数据扩容,当前同舟云学术共收录了国内外主流学术期刊6万余种,收集的期刊论文及会议论文总量共计约1.5亿篇,并以每天添加12000余篇中外论文的速度递增。我们也可以为用户提供个性化、定制化的学者数据。欢迎来电咨询!咨询电话:010-8811{复制后删除}0370

www.globalauthorid.com

TOP

Copyright © 2019-2024 北京同舟云网络信息技术有限公司
京公网安备11010802033243号  京ICP备18003416号-3